|
| Status |
Public on May 20, 2012 |
| Title |
Gene expression profile of U373MG exposed to anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids (II) |
| Sample type |
RNA |
| |
|
| Source name |
U373MG cells treated with ET-770
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: U373MG
cell type: glioblastoma
treatment: ET-770 for 24 hours at a concentration of IC50 (4.83 nM)
|
| Treatment protocol |
The cells were exposed to ET-770 for 24 hours at a concentration of IC50 (4.83 nM).
|
| Growth protocol |
The cells were maintained in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin (feeding medium).
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was isolated from the cells by using the TRIZOL Plus RNA Purification kit (Invitrogen).
|
| Label |
biotin
|
| Label protocol |
Three hundred ng of total RNA was processed for cRNA synthesis, fragmentation, and terminal labeling with the GeneChip Whole Transcript Sense Target Labeling and Control Reagents (Affymetrix).
|
| |
|
| Hybridization protocol |
Hybridization was performed at 45℃ for 17 hours. The arrays were washed and stained in the GeneChip Fluidic Station 450 (Affymetrix) by using Hybridization, Wash and Stain kit (Affymetrix).
|
| Scan protocol |
The arrays were scanned by the GeneChip Scanner 3000 7G (Affymetrix).
|
| Data processing |
The data expressed as CEL files were normalized by the robust multiarray average (RMA) method with the Expression Console software (Affymetrix).
|
| |
|
| Submission date |
Mar 20, 2012 |
| Last update date |
May 20, 2012 |
| Contact name |
Jun-ichi Satoh |
| E-mail(s) |
satoj@my-pharm.ac.jp
|
| Organization name |
Meiji Pharmaceutical University
|
| Department |
Bioinformatics
|
| Lab |
Molecular Neuropathology
|
| Street address |
2-522-1 Noshio, Kiyose
|
| City |
Tokyo |
| ZIP/Postal code |
204-8588 |
| Country |
Japan |
| |
|
| Platform ID |
GPL6244 |
| Series (1) |
| GSE36619 |
Gene expression profile of U373MG exposed to novel anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids |
|
